Skip to main content
BSX logo

Boston Scientific Corporation (BSX) Stock: Price, Forecast & Analyst Target

Boston Scientific Corporation (BSX) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $42.99 (-1.49%), as of the Nov 19, 2026 trading session; market cap $62.3B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$42.99 −$0.65 (-1.49%) Market Cap $62.3B

Boston Scientific Corporation · BSX · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-12: Boston Scientific sells procedure-specific devices used across cardiovascular care, rhythm management, endoscopy, urology and neuromodulation. Revenue is still rising, but its durability depends on cardiac rhythm management returning to growth and operating cash flow supporting a balance sheet where debt far exceeds liquid resources.

Price as of Nov 19, 2026

Key Statistics

77 of 100

MoonshotScore v2 · Boston Scientific (BSX)

Strong
Business Quality Elite (88)
Financial Safety Okay (51)
Valuation Fair (62)
Growth Durability Compounding (89)
Momentum Quiet (41)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and elite growth, though the balance sheet is only middling. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 3, 2027
  • Altman Z 3.01 · Piotroski F 6

Helping: business quality, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BSX (57 recorded, newest six shown)
RecordedScoreBand
80Exceptional
80Exceptional
81Exceptional
81Exceptional
77Strong
77Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$42.99
Change on the day-1.49%
52-week range$39.57–$101.91
Market capitalisation$62.3B—
Price / earnings (trailing)18.16
Shares traded on the day15.92M
Beta (volatility vs the S&P 500)0.59

Why Boston Scientific scores 77

Dr. Mira Sol, the Stock Expert AI TV data character
Growth Durability carries the score; Momentum is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
77Strong
  • Business Quality88
  • Financial Safety51
  • Valuation62
  • Growth Durability89
  • Momentum41

Share price, last 12 months -55.7%

$100.91 $44.70

What the price assumes

6.8% a year of free-cash-flow growth for ten years is what a $64.79B market value ( snapshot) asks for.

  • Price implies, next ten years6.8%
  • Free cash flow, last 5 years26.4%
  • Revenue, last 5 years15.2%
  • Analysts' revenue path, 2026–20305.1%

The price asks for less growth than the business has been producing. The question it leaves open is how long that pace lasts, not whether it exists. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $3.33B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 5.4% either way.

  1. +5.5%Jan ’24
  2. +6.2%Apr ’24
  3. -5.5%Jul ’24
  4. -3.3%Oct ’24
  5. +1.4%Feb ’25
  6. +6.4%Apr ’25
  7. +3.0%Jul ’25
  8. +2.5%Oct ’25
  9. -15.3%Feb ’26
  10. +10.4%Apr ’26
  11. -0.1%Jul ’26
  12. -5.3%Oct ’26
Next-session move EPS beat (11) EPS in line (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
In lineIn line-5.3%+1.7%
BeatBeat-0.1%+3.6%
BeatIn line+10.4%-4.0%
BeatIn line-15.3%-19.8%
BeatBeat+2.5%+0.4%
BeatBeat+3.0%+3.5%
BeatBeat+6.4%+8.2%
BeatBeat+1.4%+2.2%
BeatBeat-3.3%-4.6%
BeatBeat-5.5%-6.0%
BeatBeat+6.2%+4.7%
BeatBeat+5.5%+6.2%

Beats have usually been rewarded — 7 of 11 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “cyber incident”, “cardiogenic shock”, “full-year adjusted”, “high growth” — none of them came up in Q2 FY2026.
  • Getting louder: “gross margin” (3 → 7 mentions), “growth profile” (3 → 7 mentions), “supply chain” (2 → 6 mentions).
  • Gone quiet: “eps growth”, “double-digit growth”, “laac market”, “margin expansion” — regular themes last call, absent this time.

The tone held steady from one call to the next; what changed is the subject matter, not the confidence.

Our track record on this stock

Since the score went from 80 to 77 while the share price moved -12.3% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range
Band changes, newest first. “Right” means the price moved the way the change pointed over the next three months.
DateBand3 months6 monthsCall
Exceptional → Strong———
Strong → Exceptional———
Exceptional → Strong———
Strong → Exceptional———
Exceptional → Strong———
Strong → Exceptional———

None of the 12 band changes we have recorded has been graded yet; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 77% of 44 rate it a buy; the average target sits +27.1% from the price of $42.99.
  • Last 90 days: 0 upgrades and 3 downgrades among 21 rating actions.
  • Our signals: Strong band; strongest pillar Growth Durability (89), weakest Momentum (41).

Here we and the crowd agree.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $42, high $103, latest $43. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $103 $42 high $103 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $761Apr 22, 2026 · Earnings results · reported above the recorded estimate · close $622Jul 29, 2026 · Earnings results · reported above the recorded estimate · close $473Oct 28, 2026 · Earnings results · reported above the recorded estimate · close $424 Oct 17, 2025 Nov 19, 2026 · $43 $99Oct 17, 2025$101Oct 31, 2025$103Nov 14, 2025$102Nov 28, 2025$93Dec 12, 2025$96Dec 26, 2025$98Jan 9, 2026$93Jan 23, 2026$76Feb 6, 2026$75Feb 20, 2026$71Mar 6, 2026$69Mar 20, 2026$63Apr 2, 2026$64Apr 17, 2026$57May 1, 2026$53May 15, 2026$48May 29, 2026$47Jun 12, 2026$44Jun 26, 2026$45Jul 10, 2026$44Jul 24, 2026$49Aug 7, 2026$50Aug 21, 2026$48Sep 4, 2026$43Sep 18, 2026$43Oct 2, 2026$44Oct 16, 2026$42Oct 30, 2026$44Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Boston Scientific (BSX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Strong
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Neutral
ROE Moderate
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Boston Scientific (BSX), and what does it report?

Short answer · as of

Boston Scientific does not sell general hospital equipment.

It commercializes catheters, stents, implants, mapping systems, stimulators and related accessories used by interventional specialties to diagnose or treat defined conditions; revenue therefore measures device sales rather than patient volumes or procedures themselves.

Reported segment revenue is grouped into Cardiovascular and MedSurg, with Cardiovascular providing the larger pool. Consolidated results blend product families serving different clinical pathways, so strength in vascular or structural-heart therapies can coexist with weakness in rhythm management, endoscopy or urology.

2 · Latest results

What do the latest results show for Boston Scientific (BSX)?

The latest reported period brought higher revenue, gross profit and operating result than the preceding period, while net result and diluted earnings per share retreated. Separately, the estimate-comparison series recorded revenue and earnings above consensus again, extending an uninterrupted run across the displayed history.

Management frames revised guidance as a reset to a realistic baseline. It expects cardiac rhythm management to remain flat over the full year, with modest improvement later as EluPro contributes during its full launch.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$5.14B Oct 28, 2026
Latest report · revenue estimate
$5.09B Oct 28, 2026
Latest report · revenue vs estimate
Above estimate Oct 28, 2026
Latest report · EPS vs estimate
Above estimate Oct 28, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 28, 2026$5.14B$5.09B$0.7300$0.7270
Jul 29, 2026$5.44B$5.38B$0.8600$0.8350
Apr 22, 2026$5.20B$5.17B$0.8000$0.7880
Feb 4, 2026$5.29B$5.28B$0.8000$0.7810
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$5.07B$755M$0.50 (diluted)
Q4 FY2025$5.29B$672M$0.45 (diluted)
Q1 FY2026$5.20B$1.34B$0.90 (diluted)
Q2 FY2026$5.44B$907M$0.61 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Boston Scientific (BSX)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow has remained positive and exceeded capital spending throughout the displayed periods, giving Boston Scientific meaningful internally generated funding. Profitability is also substantial at the gross, operating and net levels.

Cash and short-term investments have fallen markedly across the displayed window and sit far below total debt. Including long-term investments improves the liquidity picture but does not close that gap; current assets cover current liabilities, while immediately liquid coverage is thinner.

Cardiovascular supplies the larger reported revenue pool. Weaker adoption or use across coronary, peripheral vascular and structural-heart therapies would therefore have a disproportionate effect on companywide sales and cash generation.

4 · What to check next?

What should you watch next at Boston Scientific (BSX)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027.

Consensus embeds sequential moderation in revenue and the earnings measure used for the scheduled release. Clearing that lower bar would matter less than the composition of the result: cardiac rhythm management should begin reflecting EluPro’s full launch if management’s expected improvement is taking hold.

Gross-profit conversion into operating profit, and operating profit into net income, deserve close attention after the latest divergence. Cash rebuilding also matters because recent operating cash generation was strong while cash and short-term investments remained well below debt.

A recent filing identified costs associated with exit or disposal activities. Any continuing effect should be assessed alongside management’s revised baseline rather than treated as evidence of underlying device demand.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Boston Scientific compare with its peers?

Short answer

Boston Scientific's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Boston Scientific spans coronary and peripheral intervention, structural heart, rhythm management, endoscopy, urology, pelvic health, pain treatment and neurological stimulation. Its economic exposure is therefore broader than a focused cardiac-device franchise, yet more concentrated in interventional tools and implants than a general healthcare portfolio.

That breadth does not make the revenue mix even. Cardiovascular remains the larger reported segment, while MedSurg provides exposure to gastrointestinal, pulmonary, urological and pelvic-health procedures that follow different clinical pathways.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Edwards Lifesciences Corporation (EW) Same industry, near in market value$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$29.83 Nov 19, 2026$12.5B84 5-pillar Nov 18, 2026
Medtronic plc (MDT) Same industry, near in market value$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
Stryker Corporation (SYK) Same industry, near in market value$318.15 Nov 18, 2026$121B80 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$101.47 Nov 19, 2026$19.2B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Boston Scientific (BSX) — this page$42.99$62.3B77
Gilead Sciences, Inc. (GILD) Named competitor$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Danaher Corporation (DHR) Named competitor$227.56 Nov 19, 2026$160B71 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$44.00 – $71.00
Consensus target
$53.77
Median target
$50.50

Consensus record · Captured .

Measured against a quoted price of $42.99 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 4, 2026

Transactions
22
Identified insiders
9
Purchases
6
Sales
0
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BSX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.08%$19.08MTrimmed −1.1% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Boston Scientific (BSX)?

Read these with our analysis →

Boston Scientific Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

How does EluPro affect Boston Scientific’s cardiac rhythm management outlook?

Management expects cardiac rhythm management to remain flat over the full year, with modest improvement later as the fully launched EluPro begins contributing. Its performance is therefore a direct test of whether this product area can resume growth.

What sits inside Boston Scientific’s Cardiovascular business?

The portfolio includes coronary stents, interventional tools, intravascular imaging catheters, structural-heart therapies and devices for peripheral arterial and venous disease.

Which Boston Scientific products sit outside cardiovascular care?

MedSurg serves gastrointestinal, pulmonary, urological and pelvic-health applications, while the wider portfolio includes spinal-cord stimulation, deep-brain stimulation and other neurological therapies. These businesses diversify clinical exposure beyond heart and vascular procedures.

Did Boston Scientific’s latest sales gain reach diluted earnings?

Revenue, gross profit and operating result advanced from the preceding period, but net result and diluted earnings per share declined. Sales growth alone therefore did not translate into matching per-share progression.

What is the BSX stock price today?

The last price recorded for Boston Scientific Corporation (BSX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BSX price target?

The analyst consensus price target for Boston Scientific Corporation (BSX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Cash, investments and debt; Management outlook — dated call excerpts
  • 1. What is Boston Scientific (BSX), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Boston Scientific (BSX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Boston Scientific (BSX)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Revenue by segment
  • 4. What should you watch next at Boston Scientific (BSX)?: Next earnings report; Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Recent SEC filings; Most recent periodic reports
  • 5. How does Boston Scientific compare with its peers?: Business description; Revenue by segment
  • FAQ: How does EluPro affect Boston Scientific’s cardiac rhythm management outlook?: Management outlook — dated call excerpts
  • FAQ: What sits inside Boston Scientific’s Cardiovascular business?: Business description; Revenue by segment
  • FAQ: Which Boston Scientific products sit outside cardiovascular care?: Business description; Revenue by segment
  • FAQ: Did Boston Scientific’s latest sales gain reach diluted earnings?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold BSX

Funds in our ETF coverage that list BSX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
BNY Mellon Women's Opportunities ETF (BKWO)2.57%